PL3512850T3 - Inhibitory interakcji menina-mll - Google Patents
Inhibitory interakcji menina-mllInfo
- Publication number
- PL3512850T3 PL3512850T3 PL17772585.0T PL17772585T PL3512850T3 PL 3512850 T3 PL3512850 T3 PL 3512850T3 PL 17772585 T PL17772585 T PL 17772585T PL 3512850 T3 PL3512850 T3 PL 3512850T3
- Authority
- PL
- Poland
- Prior art keywords
- menin
- inhibitors
- mll interaction
- mll
- interaction
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395618P | 2016-09-16 | 2016-09-16 | |
| PCT/US2017/051780 WO2018053267A1 (en) | 2016-09-16 | 2017-09-15 | Inhibitors of the menin-mll interaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3512850T3 true PL3512850T3 (pl) | 2023-10-09 |
Family
ID=59966892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17772585.0T PL3512850T3 (pl) | 2016-09-16 | 2017-09-15 | Inhibitory interakcji menina-mll |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10899758B2 (enExample) |
| EP (2) | EP3512850B1 (enExample) |
| JP (3) | JP2019529421A (enExample) |
| KR (1) | KR102536029B1 (enExample) |
| CN (2) | CN118359610A (enExample) |
| AR (1) | AR109658A1 (enExample) |
| AU (1) | AU2017326006B2 (enExample) |
| CA (1) | CA3036987A1 (enExample) |
| DK (1) | DK3512850T3 (enExample) |
| ES (1) | ES2948949T3 (enExample) |
| FI (1) | FI3512850T3 (enExample) |
| IL (2) | IL295972A (enExample) |
| MX (2) | MX2019003091A (enExample) |
| PL (1) | PL3512850T3 (enExample) |
| TW (1) | TWI757340B (enExample) |
| WO (1) | WO2018053267A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| SI3429591T1 (sl) | 2016-03-16 | 2023-07-31 | Kura Oncology, Inc. | Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe |
| WO2017192543A1 (en) | 2016-05-02 | 2017-11-09 | Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| JP7007302B2 (ja) | 2016-06-10 | 2022-01-24 | ヴァイティー ファーマシューティカルズ，エルエルシー | メニン－ｍｌｌ相互作用の阻害剤 |
| MX392051B (es) | 2016-09-14 | 2025-03-21 | Janssen Pharmaceutica Nv | Inhibidores espirobiciclicos de la interaccion de menina-mll |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| JP2019529421A (ja) * | 2016-09-16 | 2019-10-17 | ヴァイティー ファーマシューティカルズ，エルエルシー | ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤 |
| JP7142010B2 (ja) | 2016-12-15 | 2022-09-26 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ相互作用のアゼパン阻害剤 |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| AU2018243586A1 (en) | 2017-03-31 | 2019-10-17 | The Regents Of The University Of Michigan | Piperidines as covalent menin inhibitors |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| WO2019146740A1 (ja) * | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する環式化合物 |
| CN112105621B (zh) | 2018-03-30 | 2024-02-20 | 住友制药株式会社 | 光学活性桥型环状仲胺衍生物 |
| KR102779601B1 (ko) | 2018-08-27 | 2025-03-12 | 스미토모 파마 가부시키가이샤 | 광학 활성인 아자비시클로환 유도체 |
| IL281391B2 (en) * | 2018-09-13 | 2025-04-01 | Kissei Pharmaceutical | Imidazopyridinone compound |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| US20230030720A1 (en) | 2018-12-06 | 2023-02-02 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
| JP7344372B2 (ja) * | 2019-09-20 | 2023-09-13 | ノバルティス アーゲー | Ｍｌｌ１阻害剤及び抗癌剤 |
| WO2021060453A1 (ja) * | 2019-09-27 | 2021-04-01 | 大日本住友製薬株式会社 | 架橋型光学活性２級アミン誘導体 |
| UA129208C2 (uk) | 2019-12-19 | 2025-02-05 | Янссен Фармацевтика Нв | Заміщені спіропохідні з прямим ланцюгом |
| EP4085056A1 (en) | 2020-01-03 | 2022-11-09 | Berg LLC | Polycyclic amides as ube2k modulators for treating cancer |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| TW202200589A (zh) * | 2020-05-28 | 2022-01-01 | 瑞士商諾華公司 | Ｍｌｌ１抑制劑及抗癌劑 |
| AU2021403827B2 (en) | 2020-12-17 | 2024-07-25 | Astrazeneca Ab | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| EP4334320A1 (en) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituted spiro derivatives |
| KR20240006542A (ko) | 2021-05-08 | 2024-01-15 | 얀센 파마슈티카 엔브이 | 치환된 스피로 유도체 |
| MX2023013515A (es) | 2021-05-14 | 2024-02-29 | Syndax Pharmaceuticals Inc | Inhibidores de la interaccion de menina-mll. |
| CR20230605A (es) | 2021-06-01 | 2024-05-24 | Janssen Pharmaceutica Nv | Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos |
| US20250333421A1 (en) | 2021-06-03 | 2025-10-30 | Janssen Pharmaceutica Nv | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
| IL309359A (en) | 2021-06-17 | 2024-02-01 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
| CN116903609A (zh) * | 2021-11-05 | 2023-10-20 | 上海优理惠生医药有限公司 | 一种化合物、包含其的药物组合物及其应用 |
| WO2023084320A1 (en) * | 2021-11-11 | 2023-05-19 | V-Ensure Pharma Technologies Private Limited | Reconstitutable, single use antidiabetic compositions |
| WO2023193790A1 (en) * | 2022-04-08 | 2023-10-12 | Janssen Pharmaceutica Nv | Crystalline forms of an inhibitor of the menin/mll interaction |
| KR20250109775A (ko) | 2022-11-24 | 2025-07-17 | 오리존 지노믹스 에스.에이. | 암 치료를 위한 lsd1 억제제 및 메닌 억제제의 조합 |
| WO2024114666A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
| EP4626426A1 (en) * | 2022-11-30 | 2025-10-08 | JANSSEN Pharmaceutica NV | Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent |
| JP2025540682A (ja) * | 2022-11-30 | 2025-12-16 | ヤンセン ファーマシューティカ エヌ．ベー． | シクロブチル置換二環式化合物 |
| CN120435473A (zh) * | 2022-11-30 | 2025-08-05 | 詹森药业有限公司 | 取代的1-苯基-3,4-二氢吡啶并[3,4-d]嘧啶-2-酮衍生物 |
| AR132185A1 (es) * | 2023-03-24 | 2025-06-04 | Acerta Pharma Bv | COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA |
| WO2025067111A1 (zh) * | 2023-09-27 | 2025-04-03 | 苏州必扬医药科技有限公司 | 一种Menin-MLL相互作用抑制剂及其制备方法和应用 |
| WO2025119184A1 (zh) * | 2023-12-04 | 2025-06-12 | 首药控股(北京)股份有限公司 | 取代的多环化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69928414T2 (de) | 1998-09-18 | 2006-08-03 | Abbott Gmbh & Co. Kg | 4-aminopyrrolopyrimidine als kinaseinhibitoren |
| EP1874769B1 (de) | 2005-04-25 | 2011-09-14 | Merck Patent GmbH | Neuartige aza-heterozyklen als kinase-inhibitoren |
| WO2010066629A2 (en) * | 2008-12-09 | 2010-06-17 | F. Hoffmann-La Roche Ag | Novel azaindoles |
| GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| KR101537148B1 (ko) * | 2010-05-31 | 2015-07-15 | 오노 야꾸힝 고교 가부시키가이샤 | 푸리논 유도체 |
| AU2012318896B2 (en) | 2011-10-03 | 2017-03-02 | The University Of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
| US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| EP2878601B1 (en) * | 2012-07-27 | 2018-03-28 | Riken | Agent for treating or controlling recurrence of acute myelogenous leukemia |
| BR112015011171A2 (pt) * | 2012-11-15 | 2017-07-11 | Pharmacyclics Inc | compostos de pirrolopirimidina como inibidores da quinase |
| CA2915163A1 (en) * | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| WO2015058084A1 (en) * | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| JP6793401B2 (ja) * | 2015-03-11 | 2020-12-02 | 国立研究開発法人理化学研究所 | 難治性白血病治療薬 |
| JP2019529421A (ja) * | 2016-09-16 | 2019-10-17 | ヴァイティー ファーマシューティカルズ，エルエルシー | ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤 |
-
2017
- 2017-09-15 JP JP2019514787A patent/JP2019529421A/ja not_active Withdrawn
- 2017-09-15 EP EP17772585.0A patent/EP3512850B1/en active Active
- 2017-09-15 CN CN202410398451.9A patent/CN118359610A/zh active Pending
- 2017-09-15 CN CN201780063763.2A patent/CN110325533B/zh active Active
- 2017-09-15 ES ES17772585T patent/ES2948949T3/es active Active
- 2017-09-15 AU AU2017326006A patent/AU2017326006B2/en active Active
- 2017-09-15 MX MX2019003091A patent/MX2019003091A/es unknown
- 2017-09-15 AR ARP170102556A patent/AR109658A1/es active IP Right Grant
- 2017-09-15 FI FIEP17772585.0T patent/FI3512850T3/fi active
- 2017-09-15 KR KR1020197010730A patent/KR102536029B1/ko active Active
- 2017-09-15 CA CA3036987A patent/CA3036987A1/en active Pending
- 2017-09-15 DK DK17772585.0T patent/DK3512850T3/da active
- 2017-09-15 US US16/333,852 patent/US10899758B2/en active Active
- 2017-09-15 EP EP23167055.5A patent/EP4230627A3/en active Pending
- 2017-09-15 IL IL295972A patent/IL295972A/en unknown
- 2017-09-15 WO PCT/US2017/051780 patent/WO2018053267A1/en not_active Ceased
- 2017-09-15 IL IL265028A patent/IL265028B/en unknown
- 2017-09-15 PL PL17772585.0T patent/PL3512850T3/pl unknown
- 2017-09-15 TW TW106131767A patent/TWI757340B/zh active
-
2019
- 2019-03-15 MX MX2022013841A patent/MX2022013841A/es unknown
-
2020
- 2020-08-11 US US16/990,657 patent/US11739085B2/en active Active
-
2022
- 2022-10-06 JP JP2022161777A patent/JP2022189853A/ja active Pending
-
2023
- 2023-05-18 US US18/320,111 patent/US20240124447A1/en not_active Abandoned
-
2024
- 2024-11-08 JP JP2024195965A patent/JP2025022910A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL321844A (en) | Menin–MLL interaction inhibitors | |
| IL259560A (en) | Inhibitors of the menin-mll interaction | |
| PL3512850T3 (pl) | Inhibitory interakcji menina-mll | |
| IL251584B (en) | Dihydropyrrolopyridines ror–gamma inhibitors | |
| IL250891A0 (en) | smyd inhibitors | |
| IL246902B (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
| AU364417S (en) | Back of the case | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| GB201513481D0 (en) | Inhibitor compounds | |
| GB201403536D0 (en) | Inhibitor compounds | |
| GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
| GB201505658D0 (en) | Inhibitor compounds | |
| GB201612860D0 (en) | Inhibitors | |
| GB201501004D0 (en) | Inhibitors | |
| IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
| IL262111B1 (en) | Monovalent inhibitors of hutnfr1 interaction | |
| GB201520949D0 (en) | Inhibitors | |
| GB201401005D0 (en) | Inhibitor | |
| GB201721465D0 (en) | Inhibitors | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors | |
| GB201621619D0 (en) | Inhibitor compounds | |
| GB201616201D0 (en) | Blood-brain barrier-penetrant dopamine-B-hydroxylase inhibitors | |
| GB201522453D0 (en) | Inhibitor compounds |